top of page
Namir Hassan
CEO of Zelluna Immunotherapy
Namir Hassan joined Zelluna Immunotherapy in August 2018 to serve as Chief Scientific Officer. He has 15 years of biotech and pharma industry experience spanning from target validation through to early phase clinical trials. Over his professional career, Namir has developed extensive experience in growing scientific businesses to thrive and deliver high value. Prior to joining Zelluna, Namir was a VP at Immunocore, responsible for creating and growing the infectious disease unit as well as helping to secure up to $40M of funding for the organisation.



Speakers


















































bottom of page